Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftazidime + gentamicin is a combination of two injectable antibiotics used primarily for the treatment of severe infections caused by susceptible Gram-negative bacteria, including Pseudomonas aeruginosa. Ceftazidime is a third-generation cephalosporin (beta-lactam) antibiotic that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding protein 3 (PBP3), leading to cell lysis. Gentamicin is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and causing misreading of mRNA, which results in bacterial death. The combination may be used synergistically in severe or resistant infections but carries an increased risk of nephrotoxicity and ototoxicity; careful monitoring is required[2][4][6]. This regimen is often reserved for life-threatening or hospital-acquired infections where multidrug-resistant organisms are suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftazidime + gentamicin.